VERU INC. Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax
VERU INC. (VERU) reported Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax of -$15.68 million for the 12-month period ending 2025-09-30, per its 10-K filed 2025-12-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest · last filed 2025-12-17
- VERU INC. income (loss), including portion attributable to noncontrolling interest, before tax for the quarter ending 2024-09-30 was -$6.26M.
- VERU INC. income (loss), including portion attributable to noncontrolling interest, before tax for the quarter ending 2024-06-30 was -$10.81M.
- VERU INC. income (loss), including portion attributable to noncontrolling interest, before tax for the quarter ending 2023-09-30 was -$7.57M.
- VERU INC. income (loss), including portion attributable to noncontrolling interest, before tax for the quarter ending 2023-06-30 was -$12.47M.
- VERU INC. income (loss), including portion attributable to noncontrolling interest, before tax for fiscal 2025 was -$15.68M.
- VERU INC. income (loss), including portion attributable to noncontrolling interest, before tax for fiscal 2024 was -$35.26M.
- VERU INC. income (loss), including portion attributable to noncontrolling interest, before tax for fiscal 2023 was -$92.67M.
| Period end | Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax 3 month | Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax 6 month | Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax 9 month | Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax 12 month | Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2025-09-30 | -$15.68M 10-K · filed 2025-12-17 | ||||
| 2024-09-30 | -$6.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-17 | -$17.07M derived: sum of 2 quarters · filed 2025-12-17 | -$35.26M 10-K · filed 2025-12-17 | -$37.08M 10-K · filed 2024-12-16 | |
| 2024-06-30 | -$10.81M 10-Q · filed 2024-08-08 | -$29.00M 10-Q · filed 2024-08-08 | |||
| 2023-09-30 | -$7.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-16 | -$20.04M derived: sum of 2 quarters · filed 2024-12-16 | -$92.67M 10-K · filed 2024-12-16 | ||
| 2023-06-30 | -$12.47M 10-Q · filed 2024-08-08 | -$85.10M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |